- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 23.01. | Ovarian cancer data restores faith in Corcept's relacorilant | ||
| 22.01. | J&J says 2026 sales could top $100 billion | ||
| 22.01. | Amazon joins the AI health assistant movement | ||
| 22.01. | NICE backs Roche lupus drug that supports kidney function | ||
| 22.01. | US checks out of WHO, leaving its bill unsettled | ||
| 22.01. | 11 high-impact drugs to look out for in 2026 | ||
| 21.01. | EU approves Otsuka's long-acting HAE drug Dawnzera | ||
| 21.01. | Hopstem maps course to bring stem cell stroke therapy to US | ||
| 21.01. | ImmunityBio rises as route opens to broader Anktiva label | ||
| 21.01. | Call goes out for type 1 diabetes screening in UK | ||
| 21.01. | Data builds behind Moderna's skin cancer vaccine | ||
| 20.01. | J&J bets on Isomorphic for AI-powered drug hunt | ||
| 20.01. | ViiV ownership shifts as Pfizer sells its stake | ||
| 20.01. | Agomab and Spyglass Pharma push the IPO button | ||
| 20.01. | AstraZeneca pays $630m to get full control of AbelZeta CAR-T | ||
| 20.01. | GSK reaches $2.2bn deal to buy food allergy biotech RAPT | ||
| 19.01. | Sun Pharma says talk of $10bn Organon bid is 'speculative' | ||
| 19.01. | EU starts review of first-line Enhertu for breast cancer | ||
| 19.01. | Could Alzheimer's be predicted with a finger-prick test? | ||
| 19.01. | NICE relents, ending postcode access to prostate cancer drug | ||
| 19.01. | 'Skinny' generic Vascepa label case reaches US Supreme Court | ||
| 16.01. | Wegovy pill shows strong early uptake, as rival looms | ||
| 16.01. | Sanofi linked to takeover bid for Ocular Therapeutix | ||
| 16.01. | Ocugen shares fall, despite positive eye disorder trial | ||
| 16.01. | Autonomous AI can spot cognitive decline in medical notes |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.